Lantheus Holdings, Inc. (NASDAQ:LNTH) is Reinhart Partners LLC.'s 3rd Largest Position

Reinhart Partners LLC. trimmed its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 11.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,205,940 shares of the medical equipment provider's stock after selling 160,933 shares during the period. Lantheus comprises 4.3% of Reinhart Partners LLC.'s holdings, making the stock its 3rd biggest holding. Reinhart Partners LLC. owned approximately 1.76% of Lantheus worth $117,700,000 at the end of the most recent quarter.

Several other hedge funds also recently added to or reduced their stakes in LNTH. Kestra Investment Management LLC bought a new position in Lantheus during the 4th quarter valued at about $27,000. Summit Securities Group LLC bought a new position in Lantheus during the 4th quarter valued at about $37,000. Parkside Financial Bank & Trust grew its holdings in Lantheus by 49.4% during the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares during the last quarter. 1620 Investment Advisors Inc. bought a new position in Lantheus during the 4th quarter valued at about $125,000. Finally, Daiwa Securities Group Inc. bought a new position in Lantheus during the 4th quarter valued at about $136,000. 99.06% of the stock is currently owned by institutional investors.

Insider Transactions at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares of the company's stock, valued at $11,445,207.20. This represents a 8.07% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Mary Anne Heino sold 26,066 shares of the stock in a transaction that occurred on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director now directly owns 318,650 shares of the company's stock, valued at $24,481,879.50. The trade was a 7.56% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 36,068 shares of company stock valued at $3,008,051. Company insiders own 1.50% of the company's stock.

Lantheus Price Performance

LNTH stock traded up $1.67 during mid-day trading on Monday, reaching $83.22. The company had a trading volume of 1,241,855 shares, compared to its average volume of 1,004,822. The firm has a 50 day moving average of $89.97 and a 200 day moving average of $91.69. Lantheus Holdings, Inc. has a 12 month low of $73.11 and a 12 month high of $126.89. The company has a market capitalization of $5.76 billion, a PE ratio of 13.85 and a beta of 0.11.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The business had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. During the same period in the previous year, the company posted $1.69 EPS. Lantheus's revenue for the quarter was up .8% on a year-over-year basis. Analysts anticipate that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analyst Upgrades and Downgrades

LNTH has been the topic of several analyst reports. B. Riley cut their price target on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a report on Friday, March 21st. Truist Financial dropped their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Finally, Wall Street Zen upgraded shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $132.67.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.